Amycretin is a single-molecule agonist at both the GLP-1 receptor and the amylin receptor, being developed as a once-weekly subcutaneous injection and a once-daily oral tablet. It fuses the appetite-suppressing GLP-1 pathway that underpins semaglutide with amylin-receptor activity, the same mechanism behind cagrilintide. That dual action is why it keeps surfacing in obesity-drug discussion as a potential step beyond current single-pathway GLP-1 agonists.
Search and community interest has climbed through 2026 for two reasons. Novo Nordisk announced in mid-2025 that both the injectable and oral formulations would advance directly to phase 3 on the strength of early data, and the broader "amylin combination" class — amycretin, CagriSema and competitors — is now framed as the next front in the obesity race. Grey-market listings using the amycretin name have appeared alongside the clinical coverage.
What the evidence actually shows is early and dose-finding. In the phase 1b/2a trial of 125 participants published in The Lancet, subcutaneous amycretin produced estimated mean bodyweight reductions of 24.3% at the 60 mg dose and 22.0% at 20 mg by week 36, versus 1.1% with placebo. Lower doses gave 16.2% (5 mg, week 28) and 9.7% (1.25 mg, week 20). A separate oral study reported 13.1% at 100 mg daily over 12 weeks versus 1.2% for placebo. These are small, short, escalating-dose cohorts, not phase 3 outcomes.
The trade-off is the familiar one for incretin drugs, amplified by the pace of dose escalation. Adverse events were predominantly gastrointestinal, dose-dependent and mostly mild to moderate, resolving by study end. The headline 24.3% came from a single highest-dose arm over 36 weeks; whether that magnitude survives larger, longer phase 3 trials — and how tolerability scales at those doses — is unproven. No amycretin product is approved, so anything sold outside a registered trial is unverified in identity and purity.